ION Breast Cancer Clinical Pathways - ION Solutions
ION Breast Cancer Clinical Pathways - ION Solutions
ION Breast Cancer Clinical Pathways - ION Solutions
- No tags were found...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
5-FU (5-Fluorouracil) Leucovorin +/- Avastin (Bevacizumab) EP=Low; FN> J Clin Oncol 11:1879-1887, 1993>> Eur J <strong>Cancer</strong> 35:1343-1347, 1999>> The Lancet 355:1041-1047, 2000CapIri +/- Avastin (Bevacizumab) EP=Moderate; FN˃20%Irinotecan 80mg/m2 D1, D8(May be given as 250mg/m2 on D1 only)Capecitabine 1000mg/m2 PO BID D1-14+/- Bevacizumab 7.5mg/kg D1q 21 Day Cycle>> WorldJGastroenterol2009January28;15(4):449–456Xeloda (Capecitabine) +/- Avastin (Bevacizumab) EP=Low; FN> J Clin Onc19:4097-4106,2001FOLFIRI +/- Erbitux (Cetuximab) EP=Moderate; FN=10%-20%Irinotecan 180mg/m 2 D1, D15Leucovorin 400mg/m 2 D1, D155-Fluorouracil 400mg/m 2 IVP D1, D155-Fluorouracil 2400mg/m 2 CI over 46 hours D1, D15+/- Cetuximab 400mg/m 2 D1 (Cycle 1 only)250mg/m 2 D1, D8, D15, D22 (or q2wk equivalent)q 28 Day Cycle>> Eur J <strong>Cancer</strong> 35:1343-1347, 1999>> Br J <strong>Cancer</strong> 99:455-458, 2008Camptosar (Irinotecan) EP=Moderate; FN> The Lancet 352:1413-1418, 1998>> J Clin Oncol 21:807-814, 2003Erbitux (Cetuximab) Camptosar (Irinotecan) EP=Moderate; FN> Br J <strong>Cancer</strong> 99:455-458, 2008>> Gastrointestinal <strong>Cancer</strong>s Symposium Abstract 237, 2007Page 21 of 39© 2013 by <strong>ION</strong> <strong>Solutions</strong>. All rights reserved
Change language